Delving into the Latest Updates on Penederm, Inc. with Synapse

概览

关联

1

项与 Penederm, Inc. 相关的药物

Falecalcitriol

氟骨三醇

靶点

VDR

作用机制

VDR激动剂

在研机构

Taisho Pharmaceutical Co., Ltd. [+2]

原研机构

Kissei Pharmaceutical Co., Ltd.

在研适应症

甲状旁腺功能亢进症 [+3]

非在研适应症

寻常痤疮 [+5]

最高研发阶段批准上市

首次获批国家/地区

日本

首次获批日期2001-04-01

100 项与 Penederm, Inc. 相关的临床结果

登录后查看更多信息

0 项与 Penederm, Inc. 相关的专利（医药）

登录后查看更多信息

3

项与 Penederm, Inc. 相关的文献（医药）

1998-03-01·Journal of Dermatological Science

Comparison of butenafine, terbinafine and azole clinical efficacy in the treatment of tinea infections

作者: John Quigley ; Daniel Bucks

1998-03-01·Journal of Dermatological Science

A new fluorinated derivative of vitamin D3, ST-630, is a potent metabolic antioxidant in human keratinocytes in vitro

作者: Yulia Y. Tyurina ; Elena A. Serbinova ; Vladimir A. Tyurin ; Valerian E. Kagan

1997-01-01·Journal of Dermatological Treatment

Systemic exposure to butenafine is low after topical administration of Mentax®

作者: Alonzo, G ; Wagner, G ; Chaudhuri, B ; Bon, C ; Gibbs, L ; Brennan, B ; Chavdarian, C ; Calvarese, B

Butenafine HCl, a fungicidal agent of the benzylamine class, was applied to the skin of normal volunteers once daily for 14 consecutive days as a 1% cream formulation (Mentax'"). The doses used were approximately 2 to 20 times higher than normal therapeutic doses. Systemic exposure to butenafine was monitored by measuring levels of butenafine and selected metabolites in the plasma and urine during and after the exposure period. Plasma levels of butenafine and its M2 metabolite were low following

100 项与 Penederm, Inc. 相关的药物交易

登录后查看更多信息

100 项与 Penederm, Inc. 相关的转化医学

登录后查看更多信息